Back to Screener

Technology

CALLIDITAS THERAPEUTICS AB(CLTEF)

Live Price

Offline

$0.2458

+9.34% today

1Y Change

-92.90%

Window

Jun 25, 2025 → Jun 22, 2026

Market Cap
$11.24B
Revenue Growth
-97.6%
EPS Growth
-891.3%
Dividend Yield
0.0%

Coverage: 70 bars · Jun 25, 2025 → Jun 22, 2026

Research Briefing

A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.

Decision context

Research Snapshot

CALLIDITAS THERAPEUTICS AB (CLTEF) is a Technology stock with a market cap of $11.24B and listed on OTC. The stock last traded around $0.25 and down 92.9% across the available one-year price window (Jun 25, 2025 → Jun 22, 2026). Baseline metrics include revenue growth of -97.6%, EPS growth of -891.3%, a dividend yield of 0.0%. What stands out right now is revenue -97.6%, EPS -891.3%, free cash flow 0.0% with operating margin -31.9% and ROIC -25.3%. Valuation already assumes a fairly strong business story at price/sales 9.3. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines CLTEF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Technology peers on this page.

Sector Context

How this name stacks up against nearby peers on first-pass metrics.

Revenue Growth

Below sector median

-97.6% vs +11.9% peer median

Operating Margin

Below sector median

-31.9% vs +22.0% peer median

What Changed This Quarter

Latest report context and the signals most likely to have changed the story.

The operating picture looks softer than before

Revenue is at -97.6% and EPS is at -891.3%, with operating margin around -31.9%.

Benchmark Edge

CLTEF vs SPY, QQQ, and Sector ETFs

Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.

Shared 1Y chart + MAX history table

CLTEF

Normalized return

SPY

--

S&P 500

Excess Return

--

Relative to SPY

CLTEF Max Drawdown

-99.99%

Trailing 1Y

SPY Max Drawdown

Trailing 1Y

Benchmark comparison is loading or unavailable right now.

Calendar-Year Returns

Uses the longest available daily history for CLTEF and SPY.

Calendar-year return history is still loading or unavailable.
CA

Company Overview

CALLIDITAS THERAPEUTICS AB

OTC

Richmond, BC, Canada

Clara Technologies Corp. is a technology company specializing in AI-driven software solutions for sales professionals and e-commerce sellers, particularly those on Amazon. Its flagship product, Sales Buddi, delivers real-time AI-powered coaching, actionable insights, and personalized strategies to enhance sales performance, enabling professionals to close more deals efficiently. The platform leverages advanced hybrid AI-quantum classical models for 20-40% faster training and predictions on complex datasets, outperforming traditional systems in speed, scalability, and accuracy even with limited data. Originally focused on cloud-based tools for Amazon sellers—including product management, customer email list building, social media traffic generation via platforms like Facebook, and professional services—Clara has evolved to emphasize revolutionary sales coaching technology. Generating revenue through subscriptions and services, the company, founded in 2021 and headquartered in Richmond, Canada, plays a key role in the e-commerce and sales tech sectors by bridging AI innovation with practical business growth tools.

Leadership
Mr. Jonah Hicks
Street Address
34 - 11551 Kingfisher Drive
Mailing
Richmond, BC, V7E 3N5
Region
Richmond, BC, Canada
Last Updated
May 8, 2026

Key Fundamentals

Valuation, growth, profitability, and balance sheet signals.

Valuation

P/E
EV/EBITDA
Price/Sales
9.3
Price/Book
33.3

Growth

Revenue
-97.6%
EPS
-891.3%
Free Cash Flow
0.0%

Profitability

Gross Margin
93.6%
Operating Margin
-31.9%
Net Margin
-38.6%
ROE
-84.7%
ROIC
-25.3%

Balance Sheet

Debt/Equity
2.92
Current Ratio
3.13

Earnings Reports

No earnings data available

Latest News

No news articles available

Official Releases

Company announcements and filings-style updates.

Official
No official releases available

Next Step

Keep the research moving

After the overview, the strongest next step is usually chart context or a tighter compare set.